1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX.ST
Egetis Therapeutics AB (publ)SE flagStockholm Stock Exchange
5.92
SEK
+0.17
- -
2.24BMarket Cap
Egetis Therapeutics AB (publ)
EGTX.ST
(Stockholm Stock Exchange)

Recent

price

5.92

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.01
- -
- -
- -
- -
- -
- -
0.25
0.52
1.47
0.55
0.21
0.12
0.22
0.15
0.17
0.17
Revenue per Share
-10.33
-1.5
-1.24
-0.92
-1.61
-1.4
-1.16
-1.63
-1.58
-1.09
-2.42
-0.58
-1
-1.27
-1.12
-0.93
-0.99
Basic EPS, GAAP
-13.48
-1.07
-1.17
-1.01
-1.37
-1.63
-1.1
-1.61
-1.51
-1.11
-1.83
-0.72
-0.89
-1.08
-0.74
-0.73
-0.71
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-9.51
-1.45
-1.2
-0.88
-1.56
-1.35
-6.88
-5.84
-7.42
-8.18
-8.61
-4.1
-4.78
-4.87
-5.19
-5.23
-5.36
Book Value per Share
-1.91
3.95
1.97
1.69
3.01
1.53
11.85
5.64
4.08
4.35
2.97
0.64
0.49
0.53
0.28
-0.09
-0.3
Tangible Book Value per Share
- -
22
27
28
30
31
33
54
54
56
73
180
194
257
307
368
377
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
14
28
83
41
38
22
58
46
62
63
Sales/Revenue/Turnover
-142,557.35
- -
- -
- -
- -
- -
- -
-641.39
-308.4
-80.68
-435.43
-274.41
-876
-540.45
-698.05
-528.85
-583.86
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
3
4
4
38
- -
Depreciation Expense
-4
-33
-34
-26
-48
-44
-38
-88
-85
-61
-178
-104
-194
-327
-344
-342
-374
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-142,559.04
- -
- -
- -
- -
- -
- -
-647.29
-301.31
-74.4
-437.81
-272.85
-861.33
-567.53
-745.34
-548.88
-592.09
Profit Margin (%)
-1
88
54
47
91
48
390
304
219
245
230
114
98
242
176
13
-74
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
3
1
106
84
51
38
LT Debt
7
88
54
47
91
48
390
304
219
245
631
527
506
546
493
339
249
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
31
40
32
LT Borrowings
54
45
38
LT Finance Leases
- -
6
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
359
395
395
Market Capitalization
1,982
1,966
2,074

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
198
254
163
Cash, Cash Equivalents & STI
146
216
142
Accounts Receivable, Net
35
19
5
Inventories
1
2
2
Total Current Liabilities
247
241
237
Payables & Accruals
- -
- -
- -
ST Debt
31
40
32
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
77.69%
-10.71%
-31.28%
Free Cash Flow
28.62%
18.01%
17.81%
Net Income, GAAP
39.37%
23.52%
-0.32%
Sales/Revenue/Turnover
- -
24.87%
35.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12
14
9
11
46
2025
13
14
17
18
62
2026
13
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.26
-0.25
-0.29
-0.32
-1.12
2025
-0.18
-0.22
-0.23
-0.3
-0.93
2026
-0.24
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PaxMedica, Inc. Common Stock (PXMD)
Novan, Inc. (NOVN)
Bolt Biotherapeutics, Inc. (BOLT)
Imago BioSciences, Inc. (IMGO)
BioCryst Pharmaceuticals, Inc. (BCRX)
Concord Biotech Limited (CONCORDBIO.BO)
Business
Egetis Therapeutics AB (publ) (STO:EGTX) develops pharmaceutical treatments for serious rare diseases with unmet medical needs in the orphan drug segment; its pipeline centers on Emcitate (tiratricol), approved in the EU in February 2025 for monocarboxylate transporter 8 (MCT8) deficiency and launched in Germany in May 2025, and Aladote (calmangafodipir), a first-in-class candidate in pivotal Phase IIb/III trials (Albatross study) to reduce acute liver injury risk from acetaminophen/paracetamol overdose. Emcitate, with Orphan Drug Designation (ODD), Breakthrough Therapy Designation, and Rare Pediatric Disease Designation in the US, targets MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta); Aladote holds ODD in the US and EU. The Stockholm-headquartered company, founded in 2006 as PledPharma AB and renamed in December 2020 following the acquisition of Rare Thyroid Therapeutics International AB, operates primarily in Europe and pursues US market authorization. Recent developments include positive topline results from the ReTRIACt pivotal US study for Emcitate in November 2025; FDA rolling NDA review acceptance and Breakthrough Therapy Designation in 2025; directed share issues raising SEK 183 million in October 2025; exclusive distribution agreements with taiba rare for Gulf region early access and Er-Kim for Turkey; and leadership share purchases by the Chairman and CFO in November 2025.